26 March 2018

Vaccination is a powerful strategy to induce the activation of tumor‐specific effector immune cells, which is key for successful immunotherapy. However, the generation of effective anticancer nanovaccines is challenging. One of these challenges is the efficient co-encapsulation of antigenic peptides or proteins together with antigen-presenting cell activating adjuvants because of their differential physicochemical properties.

In a recent publication in the journal Small, Liping Qiu in the group of Carl Figdor and Martijn Verdoes turned this disadvantage into an advantage by inducing antigen assembly using immune stimulating adjuvants.

This approach resulted in the generation of nanovaccines with superior antigen/adjuvant loading efficiency. To protect nanovaccines in circulation and to introduce additional functionalities, a biocompatible polyphenol coating is installed. The resulting functionalizable nanovaccines are equipped with a pH (low) insertion peptide (pHLIP) to facilitate endolysosomal escape and to promote cytoplasmic localization, with the aim to enhance cross‐presentation of the antigen by dendritic cells to effectively activate CD8+ T cell. The paper nicely demonstrates that pHLIP‐functionalized nanovaccine can induce endolysosomal escape and enhance CD8+ T cell activation both in vitro and in vivo. The preparation of nanovaccines of the clinically relevant tumor‐associated antigen NY‐ESO‐1 and the excellent capacity to elicit NY‐ESO‐1‐specific CD8+ T cell activation, demonstrate a high potential of this functionalizable nanovaccine formulation strategy for clinical applications.
 
Publication: Endolysosomal‐Escape Nanovaccines through Adjuvant‐Induced Tumor Antigen Assembly for Enhanced Effector CD8+ T Cell Activation
 

Related news items


Laurens Verscheijden awarded doctorate degree 'cum laude'

19 January 2022

Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.

read more

Improved AI will boost cancer research and cancer care Geert Litjens receives ERC Starting Grant

13 January 2022

Geert Litjens from Radboud university medical center has received a European Research Council (ERC) Starting Grant.

read more

Understanding fluctuation variation in cognitive abilities may provide insight into lifelong learning Rogier Kievit recieves ERC Starting Grant

13 January 2022

Rogier Kievit from Radboud university medical center has received a European Research Council (ERC) Starting Grant.

read more

Looking back on RIMLS New Year celebration and awards

12 January 2022

RIMLS organized a special online New Year Celebration, together looking back at the year 2021. René Bindels reviewed 2021 together with Clasien Oomen and Dagmar Eleveld-Trancikova, looked forward towards 2022 and presented the RIMLS awards and several other prizes.

read more

Hans Jacobs receives KWF Proof-of-Concept grant to develop personalized cancer diagnostics

11 January 2022

The Dutch Cancer Society (KWF) launched a new funding program to support successful KWF researchers to translate their results into clinical practice. Hans Jacobs and his team developed a personalized blood-test to measure minimal residual disease (MRD) in patients with multiple myeloma.

read more

Radboud Postdoc Initiative (RPI) Pizza & Beer

6 January 2022

On 2 February 2022 from 17:00 - 18:00 hrs the Radboud Postdoc Initiative will host an online meeting for Postdocs (and last year PhD candidates) with the theme ‘PhD to Start Up'. The meeting will be lead by Sruthi Sreekumar.

read more